These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
263 related items for PubMed ID: 23296792
1. Fibroblast growth factor 23: associations with cardiovascular disease and mortality in chronic kidney disease. Negri AL. Int Urol Nephrol; 2014 Jan; 46(1):9-17. PubMed ID: 23296792 [Abstract] [Full Text] [Related]
4. Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study. Lioufas N, Toussaint ND, Pedagogos E, Elder G, Badve SV, Pascoe E, Valks A, Hawley C, IMPROVE-CKD Writing Committee.. BMJ Open; 2019 Feb 21; 9(2):e024382. PubMed ID: 30796122 [Abstract] [Full Text] [Related]
8. Fibroblast growth factor is associated to left ventricular mass index, anemia and low values of transferrin saturation. Eser B, Yayar O, Buyukbakkal M, Erdogan B, Ercan Z, Merhametsiz O, Haspulat A, Oğuz EG, Dogan İ, Canbakan B, Ayli MD. Nefrologia; 2015 Feb 21; 35(5):465-72. PubMed ID: 26394828 [Abstract] [Full Text] [Related]
9. FGF23: a mature renal and cardiovascular risk factor? Zoccali C, Yilmaz MI, Mallamaci F. Blood Purif; 2013 Feb 21; 36(1):52-7. PubMed ID: 23735695 [Abstract] [Full Text] [Related]
10. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations. Molony DA, Stephens BW. Adv Chronic Kidney Dis; 2011 Mar 21; 18(2):120-31. PubMed ID: 21406297 [Abstract] [Full Text] [Related]
12. FGF23 and Phosphate-Cardiovascular Toxins in CKD. Vogt I, Haffner D, Leifheit-Nestler M. Toxins (Basel); 2019 Nov 06; 11(11):. PubMed ID: 31698866 [Abstract] [Full Text] [Related]
13. The impact of diabetes mellitus on vitamin D metabolism in predialysis patients. Tanaka H, Hamano T, Fujii N, Tomida K, Matsui I, Mikami S, Nagasawa Y, Ito T, Moriyama T, Horio M, Imai E, Isaka Y, Rakugi H. Bone; 2009 Nov 06; 45(5):949-55. PubMed ID: 19631779 [Abstract] [Full Text] [Related]
14. FGF-23 and Osteoprotegerin but not Fetuin-A are associated with death and enhance risk prediction in non-dialysis chronic kidney disease stages 3-5. Alderson HV, Ritchie JP, Middleton R, Larsson A, Larsson TE, Kalra PA. Nephrology (Carlton); 2016 Jul 06; 21(7):566-73. PubMed ID: 27334353 [Abstract] [Full Text] [Related]
17. The role of fibroblast growth factor 23 in chronic kidney disease-mineral and bone disorder. Diniz H, Frazão JM. Nefrologia; 2013 Nov 13; 33(6):835-44. PubMed ID: 24158124 [Abstract] [Full Text] [Related]
18. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). Ix JH, Katz R, Kestenbaum BR, de Boer IH, Chonchol M, Mukamal KJ, Rifkin D, Siscovick DS, Sarnak MJ, Shlipak MG. J Am Coll Cardiol; 2012 Jul 17; 60(3):200-7. PubMed ID: 22703926 [Abstract] [Full Text] [Related]